Life Sciences & Healthcare

Insights and learnings for Japanese life sciences organisations that are globalising to fulfil growth ambitions. Driven by domestic economic and industry-specific challenges, many Japan-headquartered life sciences organisations are looking at greater globalisation as a catalyst for growth and innovation. This report highlights this trend via executive interviews across Japanese life sciences (LS) organisations, non-Japanese LS organisations, and cross-industry Japanese organisations.

Our 15th year analysing the forecast average internal rate of return (IRR) for the top 20 biopharma companies reveals a second year of growth to 5.9 per cent in 2024. Discover more.

The Future of Health Series is a dynamic collection of webcasts designed to spark conversations and drive meaningful change across the healthcare landscape.

In this report, Project HOPE and Deloitte US have brought together frontline healthcare workers, programme leaders, health system advisors, policy and advocacy professionals, community leaders and strategic relationships to collaborate on potential solutions for enhancing climate resilience.

Platform businesses are rewiring the traditional value chain. In nearly every industry, well-thought-out platform businesses typically beat traditional businesses because of superior unit economics and network effects.

Deloitte's Electronic Health Record (EHR) solution helps health systems execute Digital Transformation that shifts legacy models into modern best practices anchored on elevating the human experience.

From digital health to biotech and from digital therapeutics to healthcare IT innovations, there’s a community and a conversation about it at the HLTH Europe event.